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Abstract 16 
The secretion of proteins that damage host tissue is well established as integral to the 17 
infectious processes of many bacterial pathogens. However, recent advances in our 18 
understanding of the activity of toxins suggests that the attributes we have assigned to them 19 
from early in vitro experimentation have misled us into thinking of them as merely destructive 20 
tools. Here we will discuss the multifarious ways in which toxins contribute to the lifestyle of 21 
bacteria and by considering their activity from an evolutionary perspective demonstrate how 22 
this extends far beyond their ability to destroy host tissue.  23 
 24 
Main Text 25 
In the century since the existence of bacterial toxins was first conceived, we have learned 26 
many intricate details of their regulation, secretion, 3D structures, target receptors, and mode 27 
of action. Their undisputed offensive role in causing the tissue damage associated with many 28 
infectious diseases has understandably led us to view them from a disease-centric 29 
perspective. However, if we take a step back and look beyond an individual patient, the 30 
selective advantage that some toxins confer to the producing bacteria becomes unclear. While 31 
for many bacteria there is a tangible benefit to producing toxins, where they directly contribute 32 
to their replication and transmission to new hosts [1, 2], there are several for which it is not 33 
clear how causing disease symptoms is of any selective advantage to the bacteria. In some 34 
cases it can even seem disadvantageous to produce toxins, as the resulting pathology results 35 
in an evolutionary dead end for the pathogen [2].  36 
 37 
 2 
To understand this apparent paradox we need to consider the many levels at which selection 1 
works on pathogens. Our early musings on the evolution of virulence led many to believe that 2 
microbial pathogens should evolve towards a benign co-existence with their host to avoid 3 
limiting their own replication through either the death or isolation of the host. As we have 4 
learned more about how microbes transmit between hosts, and about the competition that 5 
exists between microbes within a host, we have come to understand that the evolution of 6 
virulence is considerably more complex than we originally appreciated. While a disease-7 
centric view-point will help us understand the immediate consequences of toxin expression, 8 
we need to look more broadly if we are to fully understand them. As there are many excellent 9 
reviews describing the role toxins play in causing tissue damage and disease symptoms [3-10 
5], we will instead focus on examples of bacterial toxins where the contribution to the long-11 
term existence and survival of the bacteria has been unclear until recently. By examining the 12 
less offensive, non-tissue destructive activities of bacterial toxins we will discuss their more 13 
subtle roles in subverting host immunity (defensive), and will also discuss some recent findings 14 
that suggest toxins can act in neither an offensive or defensive role, but instead provide 15 
benefits to the bacteria unrelated to a direct interaction with their host, such as facilitating 16 
biofilm formation, motility, and niche establishment. 17 
 18 
Adenylate cyclase affecting toxins: a role beyond pathogen transmission. 19 
The classic example of a bacterial toxin that affects the adenylate cyclase activity of their host 20 
is cholera toxin. However, many diverse genera of bacteria express similarly acting toxins, 21 
including other entero-pathogens such as Escherichia coli and Clostridium perfringens, but 22 
also respiratory pathogens such as Bordetella pertussis. For the entero-pathogens the link 23 
between the offensive activity of these toxins and the selective advantage they confer is clear; 24 
by interfering with the adenylate cyclase system of the cell they attach to, they activate the 25 
cell’s calcium channels leading to a release of ions from the cell into the lumen of the gut, 26 
causing the subsequent release of water to balance out ion induced osmotic stress [1]. This 27 
results in the production of diarrhoea, and the subsequent transmission and ongoing survival 28 
of the bacteria [1].  29 
 30 
It is interesting to consider the role such a toxin would play for a respiratory pathogen. 31 
Bordetella pertussis, the causative agent of pertussis (commonly referred to as whooping 32 
cough), produces two well-characterised toxins, PT (pertussis toxin) and the ACT (adenylate 33 
cyclase toxin). ACT has direct cyclase activity, whereas PT is an ADP-ribosyltransferase that 34 
modifies the alpha subunit of heterotrimeric G proteins of host cells [5]. A consequence of the 35 
aberrant signalling arising from this can be uncontrolled activation of host cell adenylate 36 
 3 
cyclase [5]. Thus, both of these toxins can cause hugely elevated levels of cAMP within host 1 
cells.  2 
 3 
At a superficial level, it might seem reasonable to suppose that toxin induced secretion of ions 4 
and water from the cells lining the lungs would cause the host to cough and expel the bacteria, 5 
resulting in its onwards transmission. However, the availability of appropriate animal models 6 
limits our understanding of the role the distinctive cough plays, as mice do not cough in 7 
response to any stimulus, and as such the contribution the cough makes to disease 8 
progression and onwards transmission of these bacteria is unproven. What we do know is that 9 
comparisons between wildtype and PT-deficient strains have identified a role for PT in 10 
modulating host immune responses [6-8] Despite the moniker, the most definite effect of 11 
pertussis in infants is leukocytosis, and PT is believed to directly contribute to this [9]. High 12 
levels of leukocytosis is associated with severe pertussis and attributed to causing pulmonary 13 
hypertension leading to cardiac failure, the main cause of pertussis related death in infants 14 
[10]. In an apparent contradiction to this, PT has been shown to inhibit chemokine production 15 
by cells in the lung shortly after initial inoculation, which reduces the recruitment of neutrophils 16 
to the site of infection [11-14]. The antibacterial functions of resident airway macrophages are 17 
also inhibited by PT, although the specific signalling mechanisms behind these are unclear 18 
[15]. These defensive effects suppress the host’s control of B. pertussis growth early in 19 
infection, aiding the establishment and development of the infection [6,14]. However, these 20 
suppressive effects appear to switch at later time points when PT production appears 21 
responsible for proinflammatory effects, either through promoting inflammation per se, or by 22 
inhibiting its resolution [16]. Thus, PT appears to have direct pathological effects such as 23 
stimulation of leukocytosis as well as defensive properties through modulation of immune 24 
functions, suggesting equally defensive and offensive roles for this toxin (summarised in fig. 25 
1). 26 
 27 
Figure 1: Contribution of pertussis toxin (PT) and adenylate cyclase toxin (ACT) to 28 
pathogenicity of Bordetella pertussis. The adenylate cyclase affecting toxins of B. pertussis 29 
contribute to disease progression via; A) PT is endocytosed into a cell, and following 30 
intracellular processing by the endoplasmic reticulum the alpha subunit is released into the 31 
cytosol. This subunit ADP-ribosylates the alpha subunit of G proteins, disassociating it from 32 
its G protein coupled receptor (GPCR) on the cell surface, inhibiting recruitment of immune 33 
cells to the site of infection. B) ACT interacts with cell surface CR3 receptors on macrophages 34 
and neutrophils, affecting antigen presentation and recruitment of the downstream adaptive 35 
immune response. The AC domain translocates to the cell cytoplasm and is stimulated upon 36 
calmodulin binding, leading to an increased cAMP levels, inhibiting proinflamatory cytokine 37 
 4 
release and complement mediated phagocytosis, and interfering with immune cell recruitment. 1 
C) PT released into the bloodstream from cells growing on ciliated epithelial lung cells has 2 
been shown to contribute development of leukocytosis. The mechanism is unclear but several 3 
have been proposed including C1) PT inhibiting migration of lymphocytes across epithelium 4 
layers. C2) PT interfering with GPCR signalling effecting immune cell recruitment. C3) PT 5 
inhibiting GPCRs required for leukocytes to stick to lymph nodes, interfering with 6 
extravasation. C4) PT stimulating the expansion of normal naïve immune cells, and not 7 
proliferation of activated cells. D) ACT inhibits biofilm formation by interfering with FHA-FHA 8 
interactions between cells. The AC domain of the toxin binds to the MCD domain at the distal 9 
tip of the FHA protein, blocking its function in biofilm.  10 
 11 
For ACT, the resulting rapid increase in cellular cAMP as a result of its adenylate cyclase 12 
activity inhibits a number of antibacterial activities including phagocytosis of the bacteria, 13 
induction of the oxidative burst in neutrophils, and inhibition of reactive oxygen species 14 
production [17-21]. The inhibition of these activities suppresses innate immunity control of B. 15 
pertussis during early infection [22,23]. Furthermore, it is thought that targeting of CR3-16 
expressing dendritic cells affects antigen processing by these cells and in doing so, affects 17 
the ensuing adaptive immune response to infection [24]. Thus ACT has key defensive 18 
activities during infection. Interestingly however, ACT has also recently been shown to affect 19 
the ability of B. pertussis to form biofilms [25]. While primarily studied in vitro, it is hypothesised 20 
that B. pertussis biofilms are important for growth and persistence in the nasopharynx during 21 
infection. The key adhesin, filamentous haemagglutinin (FHA), is heavily involved in B. 22 
pertussis biofilm formation and development [26]. Interestingly, the AC domain of ACT can 23 
bind to FHA and in doing so inhibit biofilm formation. Binding is through the catalytic domain 24 
of AC but is independent of catalytic function. Exogenous AC can also disrupt preformed 25 
biofilms [25]. Expression of FHA and AC is regulated by the activity of the Bvg two-component 26 
system [27,28]. Differential expression of FHA and AC could alter the balance between biofilm 27 
formation, non-biofilm growth and possibly dispersal of B. pertussis from established biofilms. 28 
Thus, AC could have an important role in regulating the mode of growth of B. pertussis during 29 
infection, in addition to its multiple roles in modifying host responses (summarised in fig. 1).   30 
 31 
Therefore, it appears that the contribution of adenylate cyclase affecting toxins to the lifecycle 32 
of pathogenic bacteria may be considerably more complex and involve behaviours far and 33 
beyond the offensive, playing defensive immune modulation functions, altering the mode of 34 
growth, and aiding in niche establishment and bacterial dispersal to new sites of colonisation 35 
or infection.  36 
 37 
 5 
Host-cell membrane destruction: asymptomatic carriage and niche establishment. 1 
The haemolytic capability of bacteria was one of the first true virulence factors identified for 2 
bacteria, and the major mechanism by which this occurs is through the formation of pores in 3 
the host cell membranes causing them to lyse. Several genera of bacteria utilise this type of 4 
toxin, including Listeria monocytogenes [29], Streptococcal species [30-33], Salmonella 5 
species [34, 35], and E. coli [36-38]. However, it is Staphylococcus aureus that appears to 6 
make the most use of this type of toxin, where up to seven distinct multicomponent pore 7 
forming toxins have been identified (alpha, gamma, PVL, LukAB, LukED and LukMF) [39]. 8 
The undeniable offensive capabilities of these types of toxins, and the role they play in the 9 
development of infections is clear. What is less clear is why, given that as many as 60% of us 10 
can carry this bacterium in our noses asymptomatically, does it maintain such potentially 11 
pathogenic capabilities? 12 
 13 
To understand this, we need to consider the three distinct ways in which we interact with this 14 
bacterium: asymptomatic carriage; superficial skin and soft tissue infections (SSTIs), and 15 
invasive disease (e.g. bacteraemia, pneumonia etc). Understandably much of the focus on 16 
these toxins has been on how they contribute to interactions that result in the most severe 17 
types of infection caused by this bacterium, invasive disease. Animal models clearly 18 
demonstrate the destructive contribution these toxins make to the development and severity 19 
of invasive diseases (an excellent summary table of such studies is provided in [39]). However, 20 
from an evolutionary perspective, as the bacteria rarely transmit from an invasive infection to 21 
another person, these infections represent a dead-end for the bacteria, and so the selective 22 
advantage the toxins confer to the bacteria during invasive disease is if anything, negative [2].  23 
 24 
Consideration of SSTIs does provide some explanation for the long-term benefit of producing 25 
toxins, however it requires us to merge our appreciation of offensive and defensive activities; 26 
if the cell types killed by the toxins are the cellular components of host immunity, then they 27 
can be simultaneously offensive and defensive. In addition to killing leukocytes, which enables 28 
the bacteria to survive the onslaught of the immune system, S. aureus SSTIs are notorious 29 
for the amount of purulent material that is produced, and this feature has been shown in many 30 
studies to be directly affected by toxins [40-42]. The major components of pus are bacteria 31 
and dead neutrophils, which with its physically sticky nature means it is a very effective means 32 
of transmission for S. aureus [43]. So there is a clear advantage to the production of toxins 33 
during SSTIs.  34 
 35 
Ultimately however, we need to consider the role these toxins play in what is by far its most 36 
common niche, the nose, as invasive disease and SSTIs represents only a fraction of the 37 
 6 
interactions that occur between us and this bacterium. In reality the human immune system is 1 
~1000 fold more likely to encounter S. aureus in the context of colonisation than it is to 2 
encounter it during a pathogenic infection [44] Whilst it’s tempting to think that the lysis of 3 
immune cells might facilitate the ability of S. aureus to colonise the nose, the exogeneous 4 
destruction of cells and tissue would result in the triggering of inflammatory processes, which 5 
is neither a feature associated with carriage of S. aureus or conducive to long-term 6 
colonisation of this niche. In a recent population based study, we sought to compare the 7 
toxicity of isolates from healthy noses to those from invasive diseases. As toxin production is 8 
readily switched off by spontaneous mutations in toxin regulating loci such as agr and rsp, 9 
were toxins not playing an important role during carriage, one might expect to see many of 10 
these mutants arising in the nose. However, we found the opposite, in that the carriage strains 11 
were significantly more toxic than the invasive strains [2, 45], suggesting that there is strong 12 
selection for toxin expression in this niche.  13 
 14 
We therefore need to consider what else these toxins are doing in the nose (summarised in 15 
fig. 2). There is conflicting evidence on whether S. aureus commonly forms biofilm in the 16 
human nose or lives in a more dispersed manner. With a recent study finding that 60% of 17 
chronic rhinosinusitis patient have evidence of non-invasive S. aureus biofilm in their noses 18 
[46], it is worth speculating about whether toxins contribute to this. The development of a 19 
biofilm involves initial attachment to a surface and accumulation of an extracellular matrix, 20 
which is largely comprised of cell surface polysaccharides, eDNA and proteins. During the 21 
initial attachment stages, the S. aureus beta toxin (a sphingomyelinase) has been shown to 22 
play a role in the production of an insoluble extracellular nucleoprotein matrix surrounding the 23 
cells in the biofilm matrix in vitro. Secreted beta toxin covalently cross-links with itself in the 24 
presence of DNA to form oligomers which promote biofilm formation, with beta toxin mutants 25 
not adhering as well as their isogenic counterparts in vitro [47]. Also Beta toxin has been 26 
implicated in  biofilm formation in vivo during endocarditis infections, with reduced vegetation 27 
mass formed by isogenic beta toxin mutants compared to beta toxin positive wild types [47]. 28 
In addition, alpha toxin has been shown to play a role in initial cell to cell contacts within the 29 
biofilm. Whilst alpha toxin mutants are able to colonise a surface, they don’t organise into 30 
multicellular macro-colonies and lack secondary biofilm structure, indicating a role for this toxin 31 
in the middle stages of biofilm development [48]. It is therefore possible that the selective 32 
advantage these pore forming toxins confer is to enhance colonisation of the nose via their 33 
effects on biofilm formation.  34 
 35 
Figure 2: The host-cell membrane attacking toxins of Staphylococcus aureus and their 36 
roles beyond host cell lysis. A) Phagocytosis of invading bacteria is followed by fusing of 37 
 7 
the phagosome to the lysosome, resulting in destruction of the bacteria. Staphylococcus 1 
aureus α and PSM toxins inhibit fusing of the lysosome. This enables the bacteria to escape 2 
from the phagosome into the cytoplasm, allowing intracellular niche establishment and 3 
replication. B) PSM toxins target co-habiting bacterial species within established niches aiding 4 
in competition for resources and competitive exclusion of non-kin isolates. C) PSM toxins have 5 
surfactant properties in vitro, enabling sliding movement across agar surfaces in the absence 6 
of traditional mobility structures such as flagella and pili. D) Pore forming toxins are involved 7 
at each step of Staphylococcus aureus biofilm formation. During the initial cell attachment 8 
phase, α-toxin is involved in establishing cell to cell contacts enabling the formation of 9 
secondary biofilm structures. In the later stages of the biofilm lifestyle, extracellular matrices 10 
develop, surrounding the cells within the biofilm. In the presence of eDNA, β-toxin covalently 11 
crosslinks with itself adding to this extracellular nucleoprotein biofilm matrix and contributing 12 
to the formation of complex biofilm secondary structuring. Detachment from the mature biofilm 13 
allows for dispersal to new sites of infection. PSM toxins are involved in this stage of the biofilm 14 
lifestyle, aiding release of cell clusters from the main body of the biofilm.  15 
 16 
In addition to their potential role in the formation of biofilm, we believe it is possible that pore 17 
forming toxins also enhance the ability of the bacteria to colonise the nose by manipulating 18 
rather than killing host immune cells. Recently we have shown that during the establishment 19 
of S. aureus nasal colonisation in experimental systems, there is an accumulation of 20 
phagocytes (both neutrophils and macrophages) within the nasal tissue [49]. The co-existence 21 
of these cell types (bacteria and phagocyte), each with the potential to kill the other, suggest 22 
they are existing in some sort of homeostasis, and when the following studies are considered, 23 
it is possible that the toxins are instead manipulating these immune cells to facilitate their co-24 
existence. There are several recent papers which show that once taken up by phagocytes, S. 25 
aureus pore forming toxins such as alpha toxin facilitate escape from the phagosome enabling 26 
the bacteria to enter the cytoplasm and replicate, establishing an intracellular niche [50]. A 27 
role for such toxins has been found also in the subversion of normal autophagic processes. 28 
Autophagy is an important homeostatic process in eukaryotic cells in which damaged cytosolic 29 
components are removed and recycled in double-membrane vacuoles called 30 
autophagosomes, which fuse with lysosomes and are digested [51]. Autophagy plays an 31 
important role in the host’s defence against invasive or intracellular pathogens [52-54]. S. 32 
aureus’s ability to subvert autophagy is under the control of the major regulator of toxin 33 
expression, the Agr system and has been shown to be specifically dependent upon Agr-34 
regulated expression of alpha toxin [55,56]. We have shown that during invasive disease this 35 
subversion allowed S. aureus to survive inside phagocytes [57], and speculate toxins may be 36 
 8 
functioning a similar manner during colonisation, potentially facilitating the carriage status and 1 
the bacteria’s long term survival and ongoing transmission. 2 
 3 
Surfactant-like toxins: niche establishment and providing a competitive edge. 4 
A second class of toxins that attack host cell membranes are the surfactant like phenol soluble 5 
modulins (PSMs), which to date have been found to be expressed only by Staphylococcal 6 
species. There are at least 8 genes identified that encode these short peptides (delta toxin, 7 
PSM1, 2, 3, 4, 1, 2, 3 and PSM-mec), and their mode of action is to aggregate in the 8 
lipid bilayer of host cell membranes leading to their disintegration [58]. As with the pore forming 9 
toxins discussed above, we need to consider their potential role in the nose if we are to 10 
understand the selective benefit they confer to the bacteria, and again a potential role in biofilm 11 
formation and survival inside phagocytes is a possibility (summarised in fig. 2). As with alpha 12 
toxin, PSMs have been shown to promote escape from the phagosome which facilitates 13 
cytoplasmic replication and survival inside phagocytes [59]. With regard to biofilm, it has been 14 
shown that during the later stages of S. aureus biofilm formation, PSMs are required for the 15 
development of the biofilm secondary structure. PSMs are thought to contribute to the 16 
formation of characteristic channels and macro-colonies, with PSM knock-out mutants forming 17 
smoother, thicker biofilms lacking secondary structure. PSMs are involved also in biofilm 18 
detachment and dispersal, with PSM mutants showing reduced dispersal in murine models of 19 
catheter infection [60]. PSMs may therefore contribute to transmission to new sites of infection. 20 
 21 
Another potential role for PSMs in nasal colonisation may be to enhance the ability of S. 22 
aureus to compete with other members of the nasal microflora. Individual bacterial species 23 
rarely exist in isolation but rather as multi-species populations in which highly abundant 24 
members dominate, with many lower abundance species co-occurring. Nutrient availability is 25 
a major driver of microbial competition and the battle for resources is fierce. The production 26 
of toxic compounds which supress and/or kill off competitors is a commonly deployed strategy 27 
used to competitively exclude sensitive, non-producing isolates. The production of these 28 
secreted compounds enables the producer to kill off or inhibit its rivals, and there is some 29 
evidence that PSMs can act in such a role, where PSMα1 and PSMα2 expressed by the 30 
notorious CA-MRSA lineage USA300 have been shown to exhibit considerable anti-microbial 31 
activity against Streptococcus pyogenes [61]. While still an offensive behaviour, it may be that 32 
the selective benefit these toxins confer is in the destruction of competing members of the 33 
nasal microbiome rather than host cells. 34 
  35 
The lack of any motile capabilities may provide another benefit for the expression of PSMs by 36 
Staphylococci. With no means of propulsion (flagella, pili etc), this genus of bacteria is entirely 37 
 9 
dependent upon external forces to move from one site to another, which is important as over-1 
population of a single niche would result in a rapid depletion of nutrients, and potentially a 2 
triggering of an immune response.  It is therefore interesting to note that in vitro, the surfactant 3 
effect of PSMs on the environment surrounding the bacteria has been shown to contribute to 4 
the ability of S. aureus to move across agar surfaces in a process referred to as sliding [62]. 5 
Whilst this sliding activity may be solely an in vitro phenomenon, that the expression of the 6 
PSMs is highly density dependent provides a potential explanation for how this might assist in 7 
the early colonisation of the nasal cavity as it could potentially facilitate the spreading of the 8 
bacteria across the lining of the nasal cavity once an optimal density at their initial attachment 9 
site has been reached. 10 
 11 
Protein synthesis inhibiting toxins: modulating the immune response. 12 
The inhibition of protein synthesis has catastrophic effects on host cells, and is a pathogenic 13 
approach adopted by several bacteria. One of the most notorious examples of these is the 14 
shiga toxin expressed by Shigella dysenteriae, as well as by recently emerged outbreaks 15 
strains of entero-haemorrhagic E. coli. An interesting feature of this toxin is that it is encoded 16 
on a phage, so it is arguably a phage rather than a bacterial toxin, and must therefore confer 17 
a selective advantage to both lifeforms. The exogenous damage of cells lining the gut and the 18 
ensuing inflammatory processes provide a clear benefit to both phage and bacteria as their 19 
transmission is effected by the production of diarrhoea. However, recent studies have 20 
highlighted immunomodulatory effects of this toxin which suggest that killing cells is not its 21 
sole effect. These toxins have been shown to upregulate chemokine monocyte chemotactic 22 
protein-1 (MCP-1, CCL2) and IL-8 (CCL8) [63,64], and increase expression of cellular 23 
adhesion molecules ICAM-1, VCAM-1, and E-selectin on endothelial cells [65], suggesting 24 
that the recruitment of the cellular aspects of host immunity to the infection site is interfered 25 
with. The increased inflammation associated with immune cell recruitment would further 26 
exacerbate diarrhoeal symptoms, demonstrating that these toxins contribute to the 27 
transmission of the bacteria utilising processes beyond their offensive activity.  28 
 29 
Neurotoxins. 30 
There are other classes of bacterial toxins that with our current understanding of their activity 31 
make little sense from an evolutionary perspective. One such class is the botulinum and 32 
tetanus neurotoxins, which are zinc dependent proteases that inhibit neurotransmission at 33 
neuromuscular synapses, resulting in either flaccid or spastic paralysis [66]. There is no 34 
evidence to suggest their expression directly confers an increased ability to colonise, replicate 35 
or transmit beyond the infected host. However, if we consider this lethal activity alongside the 36 
ability of these bacteria to produce spores, then perhaps we can speculate about an indirect 37 
 10 
role in transmission. Sporulation provides a long term survival strategy for the bacteria, 1 
allowing for transmission even after the host has been killed. So, perhaps by rapidly killing the 2 
host the toxin decreases the chances of the host immune system clearing the infection, 3 
facilitating maximal spore formation and enhanced transmission. Alternatively, as a member 4 
of the gut flora of several animals, it is possible that they play an as yet to be identified role in 5 
this niche. 6 
 7 
Superantigens. 8 
Superantigens are another class of bacterial toxins expressed in a wide range of bacterial 9 
genera (e.g. Yersinia, Streptococcal and Staphylococcal species) that confer no apparent 10 
benefit to the bacteria, which raises the questions of whether they exclusively function in the 11 
role of immune evasion. These toxins crosslink the class II major histocompatibility complex 12 
antigens on professional antigen presenting cells to T cell receptors, resulting in massive 13 
systemic release of pro-inflammatory cytokines, which can lead to fever, shock and death of 14 
the patient. The induction of T cell anergy is another feature of superantigens [67] and it’s 15 
tempting to speculate that at the trace levels expressed during colonisation this subversion of 16 
the immune system might facilitate colonisation. However, a recent study found that the 17 
inactivation of a superantigen in two distinct lineages of S. aureus resulted in consistently 18 
higher bacterial loads in the nose when compared to their wild type strain [68]. It is therefore 19 
clear that we do not understand the long-term benefit the expression of superantigens confer 20 
to their producing bacteria, and should perhaps be grateful that despite their ubiquitous nature 21 
they rarely exert a pathogenic effect.   22 
 23 
Conclusion 24 
In an attempt to understand the roles toxins play in the lifestyle of bacteria we have adopted 25 
a perspective beyond their direct contribution to pathogenesis, and allowed ourselves to 26 
speculate about alternative explanations for their prevalence. In doing so we believe we have  27 
demonstrated how much we have yet to learn. This is particularly important when such 28 
virulence factors are being targeted during development of novel therapeutics, where 29 
interference with the expression or activity of those produced by bacteria causing an infection 30 
could have unforeseen consequences on other bacterial behaviours. It is perhaps a semantic 31 
problem which is blinkering us, relating to the term ‘toxin’ which we understandably take to 32 
mean as having a toxic effect. However, we believe it is critical to consider the potential of 33 
each toxin to be not only offensive, but also defensive and perhaps contributing to a bacterial 34 
behaviour completely unrelated to pathogenicity, if we are ever to fully understand them and 35 
their producing microorganisms. 36 
 37 
 11 
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